Skip to main content
Clinical Trials/NCT01131832
NCT01131832
Completed
Phase 4

Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols

University of Manitoba2 sites in 2 countries71 target enrollmentSeptember 2010
ConditionsHyperlipidemia

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Hyperlipidemia
Sponsor
University of Manitoba
Enrollment
71
Locations
2
Primary Endpoint
Serum Lipids
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The substantial range of individual responsiveness to plant sterols has important ramifications. Marked differences across individuals in particular aspects of the cholesterol metabolic pathway must alter the impact of plant sterol consumption. As such, a pronounced need exists to understand the genetic and metabolic factors that explain the substantial degree of heterogeneity in response of lipid concentrations to plant sterols across individuals. The primary focus of this trial is to delineate the impact of differing cholesterol synthesis levels on response of LDL-C and other plasma lipids to plant sterol consumption. Participants pre-identified as high or low endogenous cholesterol synthesizers, according to their screening level of lathosterol to cholesterol ratios, will be given PS or a placebo containing margarine to consume under supervision for 4 weeks in a crossover design. The trial will characterize the responsiveness of the participants' total, LDL, and HDL cholesterol, as well as triacylglycerol (TG) concentrations, to plant sterol consumption. This research will determine if cholesterol synthesis phenotype predicts the responsiveness of lipids to plant sterol consumption. Variations in candidate genes involved in cholesterol metabolism will also be investigated in order to find associations with both cholesterol metabolism phenotypes and responsiveness of lipids to plant sterols. The output of this research will be to advance the knowledge of which genetic factors influence the degree of cardiovascular benefit derived from plant sterols through lipid lowering.

Registry
clinicaltrials.gov
Start Date
September 2010
End Date
February 2012
Last Updated
8 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Peter J. H. Jones

Professor, Food Science and Human Nutritional Sciences

University of Manitoba

Eligibility Criteria

Inclusion Criteria

  • fasting serum LDL cholesterol \>3.0 mmol/L
  • high or low lathosterol to cholesterol ratio

Exclusion Criteria

  • use of lipid lowering therapy
  • documented cardiovascular/atherosclerotic disease
  • inflammatory disease
  • uncontrolled hypertension
  • kidney disease
  • liver disease
  • other systemic diseases
  • chronic alcohol consumption (\> 2 servings/day)

Outcomes

Primary Outcomes

Serum Lipids

Time Frame: Baseline (Day 1,2) and Endpoint (Day 27,28) of each experimental period

Total Cholesterol, LDL-C, HDL-C, Triglycerides

Serum non-cholesterol sterols

Time Frame: Baseline (Day 1,2) and Endpoint (Day 27,28) of each experimental period

Lathosterol,Lanosterol,Desmosterol,Sitosterol,Campesterol,Cholestanol,

Genotype via single nucleotide polymorphism analysis

Time Frame: Baseline

SNP genotyping in genes related to cholesterol metabolism

Secondary Outcomes

  • Cholesterol synthesis measurement by deuterium incorporation(Endpoint (Day 27,28) of each experimental period)
  • Change in cholesterol absorption due to plant sterol consumption(Change in cholesterol absorption from control period (measured over days 24-28) to plant sterol period (days 24-28))

Study Sites (2)

Loading locations...

Similar Trials